We investigated atrial natriuretic factor (ANF) in humans, measuring plasma immunoreactive (ir) ANF (in femtomoles per milliliter), and renal, hormonal, and hemodynamic responses to ANF infusion, in normal subjects (NL) and congestive heart failure patients (CHF). Plasma irANF was 11±0.9 fmol/ml in NL and 71±9.9 in CHF (P < 0.01); the latter with twofold night ventricular increment (P < 0.05). In NL, ANF infusion of 0.10 ig/ kg per min (40 pmol/kg per min) induced increases (P < 0.05) of absolute (from 160±23 to 725±198 iseq/min) and fractional
Introduction
The physiologic significance ofsecretory granules present within mammalian atrial myocytes (1) was elucidated in 1981 by deBold and co-workers (2), who demonstrated that intravenous administration of atrial extracts to intact rats induces profound natriuresis and diuresis. Subsequently, several structurally related peptides, collectively known as atrial natriuretic factor (ANF),' have been isolated from rat and human atria, sequenced and synthesized, and shown to mimic the natriuretic and diuretic effect ofatrial extracts (3) (4) (5) (6) (7) . In addition, several other potentially important biological actions of ANF have been demonstrated in vitro and in intact animals, including relaxation of vascular smooth muscle (8, 9) , complex renal hemodynamic effects (10, 1 1), inhibition of renin, aldosterone, and vasopressin release (1 1, 12) , and blood pressure reduction (2, 1 1). Initial studies in human subjects have confirmed the natriuretic, diuretic, and blood pressure-reducing effects of ANF administration, using bolus or brief infusion techniques (13, 14) . It has been postulated that abnormal ANF secretion or responsiveness may contribute to the edema-forming states such as congestive heart failure, where increased circulating immunoreactive ANF levels have been reported (14, 15) . There are, however, no studies that have characterized the response to ANF infusion in patients with heart failure.
The present study was designed to address several issues regarding the potential physiologic role of ANF: (a) to determine the range of endogenous ANF concentration in normal subjects and patients with congestive heart failure, (b) to determine whether constant infusion of exogenous ANF induces sustained natriuresis and diuresis in normal subjects, (c) to identify potential renal, hormonal, and systemic hemodynamic mechanisms that may govern the natriuretic and diuretic response to ANF infusion, and (d) to determine whether the response to ANF administration is normal or abnormal in patients with heart failure. College. All individuals participating in this study were admitted to the Adult Unit ofthe Clinical Research Center ofNew York Hospital-Cornell University Medical College. The study consisted of three interrelated protocols ( Fig. 1) , each of which is described in detail below.
Glossary
Preparation ofANFfor human study. At the time these studies were initiated, the exact sequence of the circulating form(s) of ANF was uncertain, and a synthetic 25-residue peptide (mol wt 2,508), based on the sequence of rat auriculin B (16) and corresponding to amino acids 102-126 of the ANF precursor, was studied. Recently it has been shown that a 28-residue peptide (mol wt 3,100), termed cardionatrin I (17) or ANF 99-126, is the principal form of ANF in rat blood (18, 19) . The peptide used in these studies corresponds to residues 4-28 of the latter peptide and differs from the corresponding human sequence by a single amino acid substitution (Ile for Met at position 12); however, the 25-and 28-residue peptides have very similar biological potency both in vitro and in vivo (5) . A single 100-mg lot of rat auriculin B was used in these studies. This peptide was synthesized manually, using conventional techniques, and was purified by gel filtration, ion-exchange chromatography, and reverse-phase high performance liquid chromatography. The peptide was dissolved in sterile 0.9% saline at a concentration of 100 ;tg/ ml. The solution was resterilized by passage through a 0.22-Mgm filter (Millipore Corp., Bedford, MA) and dispensed in 0.7-ml and 5.0-ml aliquots into sealed sterile vials. At the time of dispensing, randomly selected vials were submitted for sterility and pyrogen testing. Prior to labeling ofvials, the actual peptide content ofthe dispensed solution was Blood Samples:
Urine Collections: Renal and hormonal response to ANF infusion in normal subjects (protocol I). Renal, metabolic, and hormonal responses to the different doses ofANF infusion were studied in 22 normal male subjects (protocol I; Fig. 1 ). Subjects were considered normal on the basis of physical examination, biochemical screening, and electrocardiogram. They ranged from 19 to 46 yr of age, were taking no medications, and ingested their usual diet prior to admission. All subjects were studied in the morning, after overnight fast, in the seated position. Intravenous catheters were placed bilaterally, for administration of ANF and blood sampling, respectively. Urine samples were obtained by free voiding at timed intervals. After a stabilization period of 30-60 min after intravenous catheter placement, all individuals received an oral water load of 400 ml. Renal plasma flow and glomerular filtration rate were determined using the steady-state clearances of para-aminohippurate (PAH) and inulin respectively. PAH and inulin were given as a priming bolus, followed by a continuous infusion for 45 min to achieve steady-state plasma concentrations of 2.5 mg/dl (PAH) and 25 mg/dl (inulin) (20). After completion ofa 45-min equilibration period, there were three 60-min phases of study: baseline, experimental infusion, and recovery. The baseline phase consisted oftwo 30-min urine collection periods, the experimental infusion phase consisted of three 20-min urine collection periods, and the recovery phase consisted of two 30-min urine collection periods. Urine output was replaced on a milliliter per milliliter basis throughout the study by administering oral water. The 22 normal subjects were divided into four groups. One group (n = 5) received a placebo infusion of 0.9% sodium chloride during the experimental infusion phase. The three remaining groups received ANF by continuous infusion at rates of 0.01 (n = 5), 0.03 (n = 6), or 0.10 (n = 6) gg/kg per min (4, 12, and 40 pmol/kg per min, respectively) during the experimental infusion phase. All infusions were given by a constant-rate infusion pump, with the final concentration of ANF adjusted for patient body weight. The volume administered per hour during the experimental infusion phase was 12.5 ml (placebo), 5 ml (0.01 g/kg per min), 7.1 ml (0.03 pg/kg per min), and 12.5 ml (0.10 pg/kg per min). Equal volumes of0.9% sodium chloride were given during the baseline and recovery phase for each individual. Heart rate and cuff blood pressure were recorded at 5-min intervals throughout the study. Upon completion oflead-in stabilization and each of the urine collection periods, blood samples were obtained for PAH and inulin concentrations, osmolality, plasma renin activity, aldosterone, and cortisol. Serum electrolytes, hematocrit, and serum protein (albumin and total) were obtained upon completion of lead-in stabilization at the end of each 60-min phase ofthe protocol. Blood Hemodynamic response to ANF infusion in normal subjects (protocol II). To determine whether the renal effects of ANF administration were associated with changes in cardiac output or vascular tone, we evaluated the hemodynamic responses to ANF infusion in another group of seven healthy normal subjects, ranging from 19 to 52 yr of age (protocol II; Fig. 1 ). All subjects were studied in the morning, after overnight fast, in the supine position. Under local anesthesia, a balloon-tipped, flow-directed catheter was placed percutaneously from a basilic vein in the arm to a final position in a branch of the pulmonary artery, confirmed by fluoroscopy. Cuff blood pressure and electrocardiographic heart rate were obtained at 5-min intervals. After catheter placement, there was a 2-h lead-in stabilization phase. This was followed by three phases that were identical in duration to those ofprotocol I. All subjects received a placebo infusion of0.9% sodium chloride vehicle during the baseline and recovery phases, and ANF infusion at a rate of 0.10 Itg/kg per min during the experimental phase. This infusion rate was chosen because it produced the most uniform effect on sodium and water excretion in protocol I. Recordings and urine collections were obtained upon completion ofleadin stabilization and at the end ofeach urine collection period. We recorded heart rate (HR, beats per minute), systolic (SBP) and diastolic (DBP) blood pressure (millimeters of mercury [mmHg] ), right atrial pressure (RAP, mmHg), pulmonary artery pressure (PAP, mmHg), and pulmonary wedge pressure (PWP, mmHg). Mean arterial pressure (MAP, mmHg) was estimated from the DBP, plus one third of the difference between SBP and DBP. RAP, PAP, and PWP were obtained on a strip-chart recorder as both phasic and electronically dampened mean pressures, but for the purposes ofthis study, only the mean pressures are reported. Cardiac output was determined by the thermal dilution technique, in triplicate, using 10 Hemodynamic and renal response to ANF infusion in patients with congestive heartfailure (protocol III). We then studied the hemodynamic and renal response to ANF infusion in a group of patients with chronic congestive heart failure (protocol III, Fig. 1 ). There were seven patients (six men, one woman) who ranged from 40 to 69 yr of age. This was a group ofconsecutive patients, drawn from a large population ofchronic heart failure patients who are referred to the authors (Drs. Cody and Kubo). Subjectively, all patients had a history of heart failure, including one or more ofthe following symptoms: dyspnea on exertion, paroxysmal nocturnal dyspnea, ankle swelling, or effort related fatigue. Objectively, chronic left ventricular dysfunction and dilatation were documented by cardiac catheterization, echocardiography, or radionuclide cineangiography. Patients with valvular heart disease, myocardial infarction within the preceding 6 mo, or recent acute decompensation were excluded. All heart failure patients were admitted to the Clinical Research Center for a period of 2-7 d prior to ANF infusion, receiving their maintenance dose of digoxin on an evening schedule, so that no patients received digoxin on the morning of study. All diuretics and vasodilator therapy were discontinued prior to admission, and patients were placed on metabolic sodium balance diet; six received 100 meq sodium intake, and one received 10 meq sodium intake (patient 6 in Tables II, III , and IV). All patients were studied in the morning in the supine position, after overnight fast. A balloon-tipped flow directed catheter was passed percutaneously from either a basilic vein, or an internal jugular vein, to a branch ofthe pulmonary artery. A cannula was also placed in the brachial artery of all patients. Catheters were placed using local anesthesia, and no premedication was administer Inasmuch as patients with congestive heart failure typically have very low urine flow rates, a urethral catheter was passed into the bladder ofall patients. After catheter placement and a 1-h stabilization period, a 400-ml water load (5% dextrose) was administered intravenously. PAH and inulin were then administered in a manner identical to protocol I. The three phases of this protocol and timing ofurine collections were identical to protocol I, except for omission ofrecovery-phase recordings in four ofseven patients. The experimental infusion phase consisted of administration of ANF at a rate of 0.10 IOg/ kg per min for 60 min. Hemodynamic parameters were obtained as in protocol II, except that heart rate and blood pressure were measured continuously, with the latter obtained by direct arterial recording Blood samples were obtained as outlined in protocol I, together with samples for plasma irANF concentration in the baseline state, (peripheral vein and right ventricle). Timed urine collections were also obtained for volume, PAH and inulin concentration, sodium, potassium, and osmolality. All seven patients completed and tolerated all phases of the protocol. One additional heart failure patient was initiated into this study; however, at the onset ofthe experimental infusion phase, he developed symptoms compatible with a vagal reaction. The ANF infusion was discontinued, the patient received intravenous administation of0.9% sodium chloride, and he recovered in the ensuing hour, without subsequent adverse effects. All heart failure patients were (22) . Plasma aldosterone (PA, nanograms per deciliter), and plasma cortisol (PC, micrograms per deciliter) were also determined by radioimmunoassay as previously described (11, 23) .
Radioimmunoassay ofendogenous plasma irANF concentration. The range of endogenous plasma irANF concentration was determined in peripheral venous blood from 70 normal volunteers derived from a previously characterized defined population (24) , who were studied in the seated position while on a regular diet; and 31 patients with congestive heart failure on standard digoxin and diuretic therapy. In seven supine normal subjects undergoing hemodynamic study (protocol II), simultaneous blood samples were obtained from a peripheral vein and from the right ventricle. Simultaneous peripheral vein and right ventricular samples were also obtained from the seven congestive heart failure patients in protocol III, and from 10 additional untreated congestive heart failure patients who did not receive the ANF infusion. All simultaneous blood samples for irANF were obtained at the end ofthe baseline phase, in the supine position. All blood samples were collected in prechilled Vacutainers (Becton, Dickinson & Co., Rutherford, NJ) containing potassium EDTA which were then placed on ice; plasma was obtained by centrifugation at 4VC and was stored at -40'C until assayed.
Plasma irANF was measured by radioimmunoassay after extraction on C18 Sep-Pak cartridges (Waters Associates, Milford, MA), as recently described (25) . Plasma samples (3 ml) were applied to individual prewashed cartridges, which were then washed with H20 (3 ml), 0.1% trifluoroacetic acid (TFA, 3 ml) and 10% acetonitrile in 0.1% TFA (3 ml). Immunoreactive ANF (irANF) was then eluted with 80% acetonitrile in 0.1% TFA (two washes, 3 ml each), and the pooled extract was dried overnight in a Speed-Vac evaporator (Savant Instruments, Inc., Hicksville, NY). Recoveries of ANF standard and of radiolabeled ANF (see below) added to plasma were 74±9% (SE) and 78±7%, respectively (range 58-84%); recoveries in individual samples were determined by addition of 1251I-ANF (1,000 cpm) to the plasma prior to extraction. Ofthe two radioimmunoassay procedures described previously (25) , only the homologous assay was used for data reported in this study. This assay employed antiserum raised against human ANF 99-126 or alphahuman atrial natriuretic peptide (a-hANP) (Peninsula Laboratories, Inc., Belmont, CA), at a final dilution of 1:27,000, and a-hANP as standard and tracer. The homologous assay was also used to estimate plasma irANF levels during infusion of exogenous rat auriculin B, because the latter peptide has 100% crossreactivity with the antiserum to a-hANP. Plasma extracts were reconstituted in 250 sl ofassay buffer (0.1 M sodium phosphate, pH 7.5, containing 0.3% bovine serum albumin (BSA) and 0.1% Triton X-100); duplicate I00-gl aliquots of unknowns or standard were incubated with diluted antiserum (100 Al) for 24 h at 4°C. Tracer (10,000 cpm in 100 Ml of assay buffer) was then added and the reaction continued for 18 h at 4°C. Instead ofthe polyethylene glycol precipitation method used previously (25) , bound and free peptide was separated by addition of 1 ml of ice-cold dextran-coated charcoal (1.5% charcoal/ 0.15% dextran T-70 in assay buffer); after centrifugation, both the pellet and supernatant were counted in a gamma counter. Results were calculated from standard curves of bound/free counts per minute vs. log ANF standard and were corrected for internal recovery. The sensitivity of the assay was 0.5 fmol per tube with an IC5o of 8.1±0.4 fmol. All values are expressed as femtomoles per milliliter. Preliminary studies show that the principal form of irANF measured by this assay in human plasma has a retention time on reverse-phase high-performance liquid chromatography identical to that of the 28-residue a-hANP (25) .
Statistical analysis. Analysis ofvariance for repeated measures, with subsequent Dunnett t test, was used to determine the significance of changes during time-dependent multiple observations (26) . One-way analysis of variance, with Bonferroni adjustment of the P value, was used for simultaneous comparisons ofmultiple groups. Paired or unpaired t tests were used to test the significance of single comparisons. All values are expressed as mean±standard error of the mean. Changes were considered significant, at P < 0.05.
Results
Endogeneous plasma irANF concentration. In seated normal subjects, plasma irANF concentration was 11±0.9 fmol/ml (range 1.1-27 fmol/ml). Plasma irANF was significantly higher (71±9.9 fmol/ml, range 2.1-236 fmol/ml) in 31 patients with congestive heart failure (P < 0.01, Fig. 2 a) . In seven supine normal subjects, simultaneous samples for irANF averaged 15±2.8 and 19±5.9 fmol/ml, respectively, in peripheral venous and right ventricular plasma (Fig. 2 b) . A right ventricular increment was not observed in one of the seven subjects, so that this difference did not achieve statistical significance. In 17 congestive heart failure patients, simultaneous samples for irANF concentration averaged 79±15 fmol/ml in peripheral venous plasma and 156±27 fmol/ml in right ventricular plasma (difference P < 0.01, Fig. 2 b) .
Responses to ANF infusion in normal subjects (protocol I). In normal subjects, the greatest magnitude and consistency of response to ANF occurred with infusion of 0.10 ,ug/kg per min (40 pmol/kg per min). The renal responses to this infusion rate, compared with those of individuals receiving placebo infusion are shown in Fig. 3 . Throughout the study, individuals receiving placebo demonstrated no significant change in renal excretory function or renal hemodynamic parameters. ANF infusion induced significant increases in UNaV, V, and both CosM and CH20. A prompt onset of these responses was noted within the first collection period (E1), with steady-state responses achieved during the remainder ofthe infusion phase (E2, E3). Comparing baseline (B2) values with the steady-state response ofthe infusion phase (E3), UNaV increased from 160±23 to 725±198 ,eq/min (P < 0.05), with an increase of FENa from 1 to 4% (P < 0.05). V increased from 10±1.6 to 20±2.6 ml/min (P < 0.05), with Less consistent responses were noted with lower rates ofANF infusion, i.e., 0.01 and 0.03 ug/kg per min (4 and 12 pmol/kg per min, respectively). Fig. 5 summarizes the steady-state values of renal parameters and PRA for individuals in the placebo infusion group, and the three ANF infusion groups. Each parameter (V, UNaV, FF, and PRA) changed consistently and reversibly in subjects receiving the highest infusion rate (0.10 ,ug/kg per min) whereas none of these parameters was altered during placebo administration. The mean changes induced by infusion of 0.03 or 0.01 eg/kg per min were not significant. Reversible increases in V, UNaV, and FF and reversible decreases in PRA were, however, noted in at least three of six subjects receiving the 0.03 ug/kg per min and in one subject receiving 0.01 sg/kg per min. Decreases in PA were also observed in these subjects (not shown). Thus the threshold response to exogenous ANF infusion occurs at a rate of 0.03 ag/kg per min (12 pmol/kg per min) or less in normal subjects. The plasma irANF concentrations (fmol/ml) achieved at the end of the infusion for the four groups were: 19±3 (placebo), 49±11 (0.01 infusion), 238±70 (0.03 infusion), and 868±54 (0.10 infusion). The responses of HR and blood pressure for the four groups ofseated normal subjects are summarized in Fig. 6 . A significant change in SBP was observed during the ANF infusion of 0.10 leg/kg per min, where the decrease to 104±5 at the end of the infusion, and continued reduction to 102±5 by the end of recovery, was significant (P < 0.05). There was no significant change in DBP for any of the groups throughout the study.
Hemodynamic responses to ANF infusion in normal subjects (protocol II). Inasmuch as the ANF infusion of 0.10 Ag/kg per min resulted in consistent renal and metabolic changes, we investigated the hemodynamic characteristics of the response to this rate of ANF infusion in supine normal subjects (Fig. 7 a, and Table II) . In response to ANF infusion, the only significant hemodynamic alteration was a reduction of PWP from 11± 1 to 7±1 mmHg (P < 0.05), which persisted throughout the first stage of recovery. There was no significant change in arterial pressure, CI, or systemic vascular resistance. ANF infusion in these individuals was associated with a peak plasma ANF concentration of 710±118 fmol/ml, and an increase of V (from 6.4±0.7 to 13.8±2.0 ml/min, P < 0.05) and UNaV (from 217±69 to 504±193 ,ueq/min, P < 0.05). These responses were comparable, although somewhat less, to the changes elicited by this dose in seated subjects.
Hemodynamic and renal responses to ANF infusion in patients with congestive heart failure (protocol III). Based on the observed changes in normal subjects, ANF was administered to seven patients with chronic congestive heart failure at an infusion rate of 0.10 Ieg/kg per min, and complete hemodynamic, renal, and metabolic characterization was obtained. The hemodynamic responses to ANF administration are summarized in Fig. 7 b and Table II . Compared with baseline values, the following significant hemodynamic changes were observed: PWP decreased from 31±4 to 25±5 mmHg (P < 0.05); CI increased from 1.77±0.06 to 2.07±0.13 liters/min per m2 (P < 0.05); and SVR decreased from 1,831±208 to 1,597±243 dyn * s cm-5 (P < 0.05). Significant changes in blood pressure were not observed. The baseline renal functional parameters of heart failure patients were markedly abnormal compared with those of normal individuals (Table III) ,gg/dl. These changes were not significant by paired t test, although nonparametric analysis of the 50% reduction of plasma aldosterone was significant (Wilcoxon, P < 0.05). There was no significant change in serum electrolytes, creatinine, BUN, or serum or urine osmolality (not shown).
Comparison ofnet changes in renal excretoryfunction. Fig.  8 summarizes the net change in V and UNaV during the experimental phase for all seated normal subjects and heart failure patients studied. In normal subjects, the renal excretory responses to ANF infusion were dependent on the dose of ANF administered. For individuals receiving the placebo infusion, the net change in V was 90±41 ml/60 min and in UNaV was -644±429
,geq/60 min. Infusion of ANF at a rate of 0.01 gg/kg per min resulted in an increase of V of 159±92 ml/60 min and UNaV of 540±1,325 geq/60 min. Placebo and 0.01 responses were not significant compared with baseline. Infusion of ANF at a rate of0.03 ug/kg per min resulted in a net increase of V of291 ±101 ml/60 min, and UNaV of 6,362±2,511 ueq/60 min (P < 0.05 and <0.07, respectively). Infusion of ANF at a rate of 0.1 ug/ kg per min increased net V by 572±90 ml/60 min and UNaV by 27,760±8,632 ;ieq/60 min (both P < 0.01). Similar increments were observed in the supine subjects studied under protocol II (249±82 ml/60 min and 12,639±4,063 geq/60 min, both P < 0.05). In contrast, patients with congestive heart failure demonstrated minimal net changes in V (27±14 ml/60 min) and UNaV (1220±907 ueq/min) at the ANF infusion rate of0. 10 ,ug/kg per min. These responses were considerably less than those of normal subjects who received the 0.03 ,gg/kg per min infusion, and, except for one patient, were within the range observed with placebo infusion.
Effect of ANF infusion on the intravascular compartment. pine normal subjects (protocol II), and supine heart failure padividuals who received ANF infusion of 0.01 or 0.03 ,ug/kg per tients (protocol III). In normal subjects, administration of ANF min, hematocrit and serum protein concentration were not resulted in a significant and reversible increase of hematocrit changed significantly. In contrast to the normal subjects, there from 45.7±0.08 to 48.6±0.9 vol % (seated subjects), and was no significant change ofhematocrit, albumin, or total protein 41.5±1.2 to 43.7±1.4 vol % (supine subjects), both P < 0.05 during ANF administration in patients with congestive heart compared with their respective baseline values. Serum albumin failure. (g/dl) also tended to increase in both groups although these changes were not statistically significant. Total protein (g/dl) Discussion increased reversibly from 6.8±0.1 to 7.3±0.3 in seated normal subjects, and from 6 Our data define a broad range ofimmunoreactive ANF concentration in the plasma of normal subjects on random sodium intake and demonstrate a significant increase in circulating ANF levels in patients with congestive heart failure. The latter finding is consistent with earlier preliminary reports (14, 15) . In our series, plasma irANF was, on average, sevenfold higher in heart failure, with 80% of the patients having frankly elevated levels. A subset of patients had levels in the normal range, but further study is needed to better define the determinants of the broad range of irANF levels in normal subjects as well as heart failure patients. The increased irANF concentration found in right ventricular compared with peripheral venous blood suggests that ANF is secreted by the heart, most likely via the coronary sinus (28) . This gradient within the heart was statistically significant and of greater magnitude in the patients with congestive heart failure, indicating that hypersecretion of ANF is a major determinant of the increase in plasma ANF in, heart failure. In view .of the evidence that blood volume redistribution, or other maneu~ers which acutely increase atrial stretch, provoke increases in ANF secretion (25, 29, 30) , it seems probable that chronic increases in atrial wall tension contribute to the elevations in plasma ANF in patients with heart failure. This hypothesis is supported by the recent study of Bates and co-workers (31) .
The finding that ANF infusion leads to significant reductions in plasma renin and aldosterone in seated normal subjects is consistent with earlier experiments showing that ANF decreases renin secretion rate (1 1, 32) and plasma renin and aldosterone (1 1) in intact animals and also inhibits aldosterone production in vitro (33) (34) (35) . The failure to demonstrate suppression of renin and aldosterone in recent clinical studies (13, 14, 27 ) is probably attributable to the fact that measurements were performed under non-steady-state conditions and/or in supine subjects, in whom the renin-angiotensin-aldosterone axis is already relatively suppressed. It has been postulated that the ability ofANF to suppress renin secretion, whether or not direct effects on the juxtaglomerular cells are involved, may depend on an intact renal hemodynamic response to the peptide (36) (37) (38) , and it has been shown that direct adrenal effects contribute to the aldosteronelowering effect ofANF in vivo under certain circumstances (36) (37) (38) . Our studies do not provide further definition of the mechanisms involved but are consistent with these observations. It is ofinterest, in this regard, that in heart failure patients, who were refractory to the renal effects of ANF, plasma renin levels were not significantly decreased, consistent with an inability to increase sodium delivery to the macula densa during ANF infusion. Nonetheless, plasma aldosterone fell, on average by 50%, a response which was probably of biological significance.
In contrast to results obtained in the intact dog (11) , our data suggest that ANF infusion may tend to lower plasma cortisol in humans. ANF is known to inhibit steroidogenesis largely at the early steps of the biosynthetic pathway (34), and there is evidence of species differences in its specificity for inhibiting aldosterone production, in that ANF has been shown to also inhibit glucocorticoid production in bovine (35) , but not rat (33) , adrenal cells in vitro. More striking was our finding of a marked rebound in cortisol (and, to a lesser extent, aldosterone) after discontinuation of the ANF infusion. Further study is needed to define the mechanism of this effect.
In normal individuals, the sustained increases in sodium excretion and urine flow rate elicited by the highest rate of ANF infusion were associated with a significant increase in filtration fraction, a pattern of renal hemodynamic response similar to that demonstrated in experimental animals (1 1, 32, 39) . It has been proposed that the renal hemodynamic actions of ANF (e.g., increases in GFR and possibly blood flow redistribution, together with secondary impairment of tubular sodium reabsorption), may be largely responsible for the potent natriuretic effect of ANF (3, 10, 11, (39) (40) (41) . One finding of the present study that was not anticipated by prior studies in animals was the rather marked and consistent increase in free water clearance observed in hydrated normal subjects. In the setting of a depressed baseline urine osmolality, this finding probably reflects increased free water formation in the thick ascending limb of Henle's loop, which would imply increased delivery of sodium to that nephron segment while sodium reabsorption is maintained; this hypothesis would be consistent with available micropuncture data (3, 39) and further suggests that a large portion of the increase in excreted sodium is derived from portions of the nephron proximal to the ascending limb (3). Because our subjects may have received a submaximal water load, however, we cannot entirely exclude the possibility that the increase in free water resulted from events in the collecting duct, even including inhibition of vasopressin release and/or antagonism of vasopressin action. In this regard, ANF has been shown to decrease plasma vasopressin in dehydrated or hemorrhaged animals (12) and to antagonize vasotocin-induced water transport by the toad urinary bladder (42) . Further study will therefore be required to clarify the mechanism(s) of ANF-induced water diuresis.
In patients with heart failure, there was a marked diminution of the renal responses to exogenous ANF. Given that these patients generally had increased circulating levels ofthe endogenous hormone, the present studies raise the possibility that a decreased renal responsiveness to ANF could contribute significantly to the pathogenesis ofsodium and water retention in this edematous disorder. In considering the mechanisms responsible for the attenuated response to ANF infusion in heart failure, it should be noted that, under basal conditions, many ofthe patients studied were retaining sodium while on a 100-meq sodium diet. This would be consistent with a previous study by our group (43) demonstrating that only 50% of such patients achieved sodium balance at this level of intake, while the remainder continued to avidly retain sodium. The responsible mechanism could not be identified, but this phenomenon was associated with different patterns of renin-angiotenin system activity. Indeed, the present data provide evidence for some degree of heterogeneity in ANF responsiveness among heart failure patients, in that at least one patient (patient 4, Table III) demonstrated a response to ANF administration that was not unlike that observed in normal subjects. This patient, who was in sodium balance at the time of the study, had the least severe heart failure, as judged by right atrial and pulmonary wedge pressures (Table II) , lack of activation of the renin-aldosterone axis (Table III) and a normal level of plasma irANF (2.1 fmol/ml). Thus, our findings do not permit a clear cut distinction between the two possible explanations for refractoriness to ANF in heart failure-namely, either a generally decreased end-organ responsiveness associated with chronically elevated circulating levels (i.e., receptor "down-regulation"), or a more specific renal hyporesponsiveness due, for instance, to baseline renal hemodynamic abnormalities. The latter hypothesis would be consistent with the observation that the three patients in whom GFR tended to increase (patients 2, 4, and 7) also had a natriuresis, albeit attenuated, in response to ANF (Table III) . Furthermore, the fact that ANF lowered plasma aldosterone in patients with CHF (Table III) speaks against a generalized down-regulation of its receptors.
Our data indicate that ANF infusion in normal subjects produces hemoconcentration of far greater magnitude than could be expected on the basis of renal fluid losses alone. An increase in hematocrit was also noted by deBold and co-workers in their initial report using bolus infusion of crude atrial extracts (2) and has been demonstrated during continuous infusion of synthetic ANF in dogs (1 1) . In the present study, we observed a significant increase ofhematocrit in normal subjects in both the seated and supine positions. This was associated with a significant increase of total protein and, to a lesser degree, serum albumin. Both hematocrit and protein decreased to near-baseline levels after (1 1) , and suggests that the peptide increases capillary hydrostatic pressure and/or permeability. With regard to the latter possibility, it is noteworthy that ANF receptors are present in cultured endothelial cells (44) , and that endothelial binding sites are rather prominently labeled in autoradiographic studies in the intact animal (45) . An interesting observation in our studies was the absence of change in hematocrit or protein concentration in the patients with congestive heart failure. This could not be attributed to differences in body position, as both seated and supine normal individuals demonstrated this hemoconcentrating effect. Although the reasons for this attenuated response remain to be defined, it is worth considering that increased interstitial fluid pressure in heart failure would likely oppose any substantial fluid shift induced by an increase in capillary permeability. The mechanism responsible for this fluid shift is an area Clearly deserving of further investigation, because it suggests an additional mechanism through which ANF might contribute to intravascular volume regulation.
The systemic hemodynamic response to ANF infusion observed in these studies is complex, and cannot be totally attributed to intravascular volume contraction. Although ANF is known to relax precontracted vascular smooth muscle in vitro, the significant blood pressure reduction induced in normotensive and certain hypertensive animal models has been ascribed to reduction of cardiac output (46) (47) (48) . In our supine normal subjects, ANF administration was associated with a significant reduction of pulmonary wedge pressure and to a lesser degree, right atrial pressure; however, there was no significant change in blood pressure, cardiac output, or calculated systemic vascular resistance. This is in contrast to the results of Weidmann et al.
(27) who noted a significant decrease of systolic and diastolic blood pressure, when ANF was given as a combination ofbolus and sustaining infusion. In our study, constant ANF infusion did decrease systolic blood pressure in the seated normal subjects.
In this group, preload reduction by ANF might be expected to cause a pronounced fall in cardiac output, so that systolic blood pressure would be more likely to decrease, an effect which might be exaggerated following bolus administration (13). The patients with congestive heart failure, whose baseline state is characterized by a markedly reduced cardiac index and increased systemic resistance, had a somewhat different profile of response. These individuals demonstrated a small, but significant reduction of pulmonary wedge pressure from very high basal levels, and a significant increase of cardiac index and reduction of systemic vascular resistance. The hemodynamic effects of ANF could be due to alteration in preload conditions of the heart, as a result ofeither a transmembrane fluid shift at the level of the capillary or venule, with a reduction of venous volume, or an increase of venous capacitance due to a direct venodilating effect. This is consistent with the reduction in cardiac filling pressures in supine normal subjects without apparent effect on cardiac output. A reduction in preload could explain the overall hemodynamic response to ANF in congestive heart failure. In these patients, where ventricular function is on the steep portion ofthe pressurevolume curve, preload reduction could decrease ventricular distention, with improvement of overall function. This improvement would translate into an increase ofcardiac output, perhaps with an autoregulatory reduction of systemic vascular resistance. This would therefore not produce a net change in mean arterial blood pressure. This hemodynamic response to ANF would be analogous, in many respects, to the responses evoked by pharmacologic intervention with low-dose nitroglycerin or loop diuretics. In view of in vitro (8-10) and intact animal (48) data, we cannot exclude a direct vasodilator effect of ANF on arterial smooth muscle, particularly in heart failure patients where the basal state is characterized by excessive vasoconstriction. Further evidence for a direct vasodilator effect of ANF is the observed increase offorearm blood flow following administration ofANF into the brachial artery of normal subjects and patients with heart failure (49) . Additional studies will be necessary to define further the vascular and cardiac effects ofANF infusion in heart failure.
In conclusion, the present study has identified three general categories of steady-state response to ANF in humans: (a) natriuresis and diuresis, associated with alteration of renal hemodynamics, manifest primarily by an increase of filtration fraction; (b) suppression ofplasma renin and aldosterone levels; (c) hemodynamic effects consistent with preload reduction due either to a vasodilating effect, or to a transcapillary fluid shift, resulting in hemoconcentration. Although detectable responses were elicited by lower infusion rates in some normal individuals, further study is required to define the physiologic significance of these actions. The refractoriness to the renal and hemoconcentrating effects of ANF infusion in patients with congestive heart failure, where endogenous plasma irANF is increased, suggests that decreased responsiveness to the endogenous hormone may play a role in the pathogenesis ofsodium and water retention in this disorder.
